Lists of people executed in the United States

STANDIGM TO ATTEND BIO-EUROPE® 2022

Retrieved on: 
Tuesday, October 18, 2022

CAMBRIDGE, England, Oct. 18, 2022 /PRNewswire/ -- Standigm, the workflow AI-driven drug discovery company, today announced that it will be represented at the 28th annual BIO-Europe taking place October 24–26, 2022 in Leipzig, Germany. After being delivered digitally over the last two years, the event is expected to bring together over 4,000 executives from biotech, pharma and finance companies to engage in 27,000+ one-to-one meetings.

Key Points: 
  • CAMBRIDGE, England, Oct. 18, 2022 /PRNewswire/ -- Standigm , the workflow AI-driven drug discovery company, today announced that it will be represented at the 28th annual BIO-Europe taking place October 2426, 2022 in Leipzig, Germany.
  • Standigm business development (BD) team and Standigm UK members including CBO Carl Foster will be attending, presenting the company profile, AI technologies and AI-driven pipelines.
  • "We are excited to be providing an inside look into Standigm at the upcoming BIO-Europe Conference and are looking forward to having meaningful partner discussions," said Jinhan Kim, CEO and Co-founder of Standigm.
  • Pursuing full-stack, AI-driven industrializing drug discovery, Standigm has achieved the automation of molecular design workflow, and the automation effort has been expanding to the whole drug discovery process on the basis of Standigm AI platforms, including Standigm ASK for novel target discovery and Standigm BEST for novel compound generation.

Microbot Medical Completes GLP Animal Study for the LIBERTY® Robotic System

Retrieved on: 
Thursday, October 13, 2022

HINGHAM, Mass., Oct. 13, 2022 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) announced a significant development milestone as it completed the GLP animal study for the LIBERTY Robotic System, the first disposable robotic system being developed for endovascular procedures.

Key Points: 
  • HINGHAM, Mass., Oct. 13, 2022 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) announced a significant development milestone as it completed the GLP animal study for the LIBERTY Robotic System, the first disposable robotic system being developed for endovascular procedures.
  • During the GLP animal study, the physicians conducted pre-determined 63 navigations to the targeted sites using the investigational LIBERTY Robotic System and performed an equal number of procedures manually.
  • For the target sites reached, the physicians graded the LIBERTY Robotic system at the highest grade.
  • We are very proud and excited of how LIBERTY performed during the GLP animal study, commented Dr. Eyal Morag, Chief Medical Officer of Microbot.

Sintetica establishes US entity

Retrieved on: 
Friday, October 14, 2022

On July 14, 2022 Sintetica established its subsidiary Sintetica US, headquartered in Princeton, New Jersey, headed by leading pharma expert Frank Mullery (President-Sintetica US).

Key Points: 
  • On July 14, 2022 Sintetica established its subsidiary Sintetica US, headquartered in Princeton, New Jersey, headed by leading pharma expert Frank Mullery (President-Sintetica US).
  • Sintetica will also continue to service its B2B partners in the US through its existing agreements.
  • Frank Mullery, President of Sintetica US affirms: "I am honored to have the opportunity to lead the Sintetica US team.
  • Sintetica is uniquely positioned with a strong core business, best in class research and development, high quality Swiss manufacturing, and a valuable pipeline.

Sintetica establishes US entity

Retrieved on: 
Friday, October 14, 2022

On July 14, 2022 Sintetica established its subsidiary Sintetica US, headquartered in Princeton, New Jersey, headed by leading pharma expert Frank Mullery (President-Sintetica US).

Key Points: 
  • On July 14, 2022 Sintetica established its subsidiary Sintetica US, headquartered in Princeton, New Jersey, headed by leading pharma expert Frank Mullery (President-Sintetica US).
  • Sintetica will also continue to service its B2B partners in the US through its existing agreements.
  • Frank Mullery, President of Sintetica US affirms: "I am honored to have the opportunity to lead the Sintetica US team.
  • Sintetica is uniquely positioned with a strong core business, best in class research and development, high quality Swiss manufacturing, and a valuable pipeline.

Implantica announces Spire Manchester Hospital in UK begins operating with RefluxStop™

Retrieved on: 
Thursday, October 13, 2022

VADUZ, Liechtenstein, Oct. 13, 2022 /PRNewswire/ --Implantica AG (publ), a MedTech company at the forefront of bringing advanced technology into the body, announces that the RefluxStop procedure to treat acid reflux is now being successfully implemented at Spire Manchester Hospital, part of the Spire Healthcare Group, with a network of 39 hospitals and 8 clinics across England, Wales and Scotland.

Key Points: 
  • VADUZ, Liechtenstein, Oct. 13, 2022 /PRNewswire/ --Implantica AG (publ), a MedTech company at the forefront of bringing advanced technology into the body, announces that the RefluxStop procedure to treat acid reflux is now being successfully implemented at Spire Manchester Hospital, part of the Spire Healthcare Group, with a network of 39 hospitals and 8 clinics across England, Wales and Scotland.
  • Mr. Paul Goldsmith, General and Upper GI Surgeon, consultant at Spire Manchester Hospital, recently successfully treated the first patient with the RefluxStop method.
  • "I am very happy to be one of the first surgeons in the UK to offer RefluxStop, which offers a surgical option for all anti-reflux patients including those who may have not been eligible for surgery in the past," said Mr. Paul Goldsmith.
  • "We consider it a milestone that the RefluxStop procedure is being offered at Spire Manchester, part of the Spire Healthcare Group which is the second largest provider of private healthcare in the UK with 47 hospitals and clinics.

Stader Update - Record-Breaking Launch on NEAR Blockchain

Retrieved on: 
Tuesday, October 11, 2022

Last month, on September 16th , Stader launched its upgraded NearX on the NEAR Blockchain.

Key Points: 
  • Last month, on September 16th , Stader launched its upgraded NearX on the NEAR Blockchain.
  • These include:
    Staking Competition : Users with a minimum stake of 500 NEAR stand to earn additional 50 NEAR in rewards.
  • As the first multi-chain protocol to bring liquid staking to NEAR, Stader will bring its cross chain expertise and help strengthen the NEAR staking ecosystem.
  • Also, Stader will support decentralization of $NEAR as users will stake with a carefully selected set of best performing yet low voting power validators.

Microbot Medical Enhances Strategic Focus on its Endovascular Solutions

Retrieved on: 
Tuesday, October 11, 2022

The Company is planning to focus its strategic efforts on the growing endovascular space and advancing the LIBERTY Robotic System to achieve its regulatory and commercial milestones, as well as expanding the LIBERTY ecosystem.

Key Points: 
  • The Company is planning to focus its strategic efforts on the growing endovascular space and advancing the LIBERTY Robotic System to achieve its regulatory and commercial milestones, as well as expanding the LIBERTY ecosystem.
  • Microbot Medical Inc. (NASDAQ: MBOT) is a pre-clinical medical device company that specializes in transformational micro-robotic technologies, focused primarily on both natural and artificial lumens within the human body.
  • Additional information on risks facing Microbot Medical can be found under the heading Risk Factors in Microbot Medicals periodic reports filed with the Securities and Exchange Commission (SEC), which are available on the SECs web site at www.sec.gov.
  • Microbot Medical disclaims any intent or obligation to update these forward-looking statements, except as required by law.

Indigenized Energy Initiative Founder and CEO Chéri Smith Selected as a 2022 MIT Solve Indigenous Communities Fellow

Retrieved on: 
Tuesday, October 11, 2022

BERKELEY, Calif., Oct. 11, 2022 /PRNewswire/ -- Indigenized Energy Initiative (IEI), an Indigenous-led nonprofit organization with the mission of supporting Native American tribes on their self-determined path to energy independence, economic prosperity, and a restoration of sovereignty and hope, announced today that Founder and CEO Chéri Smith has been selected as a 2022 MIT Solve Indigenous Communities Fellow.

Key Points: 
  • I am humbled and honored to be selected as a 2022 MIT Solve Indigenous Communities Fellow -Chri Smith, IEI founder, CEO
    Solve is an initiative of theMassachusetts Institute of Technology (MIT)with a missionto drive innovation to solve world challenges.
  • Solve's Indigenous Communities Fellowship seeks solutions that consider both technology and traditional Indigenous knowledge to support and scale positive impact in tribal communities.
  • "Chri Smith wasselected because she and her team are taking aninclusive, systems-based approach toleveraging the power of clean energy to address significant climate, economic, and energy challenges faced by Native American communities," said Aaron Slater, senior officer, Indigenous Communities, for MIT Solve.
  • "I am humbled and honored to be selected as a 2022 MIT SolveIndigenous Communities Fellow," said Chri Smith, IEI founder, CEO,and descendant of the Mi'Kmaq Tribe.

Kdrive launches an application that combines Drive-to-earn and GameFi to optimize income for everyone

Retrieved on: 
Friday, October 7, 2022

In this mostly automatable and virtual day and age, the demand and desire for daily physical travel are experiencing a significant decline.

Key Points: 
  • In this mostly automatable and virtual day and age, the demand and desire for daily physical travel are experiencing a significant decline.
  • Within the ecosystem of KDrive, users are entitled to a number of fascinating in-app features:
    Drive-To-Earn: In essence, KDrive is a financial game capable of providing users with a practical income through the means of NFTs.
  • There are also a number of gaming modes for users looking for a change, including KDrive.
  • Collaboration with taxi lines to further promote awareness as well as offer an alternative source of income for taxi drivers.

2022 US, UK and Japan Nontuberculous Mycobacteria Market Size and Trend Report to 2031 - Players Include Revimmune, Novartis, Insmed and Nobelpharma - ResearchAndMarkets.com

Retrieved on: 
Thursday, October 6, 2022

Overview of diagnostics and treatment, treatment profiles of combination therapy for different NTM strains.

Key Points: 
  • Overview of diagnostics and treatment, treatment profiles of combination therapy for different NTM strains.
  • Key topics covered for nontuberculous mycobacteria drugs in the 3MM include trends, pipeline and market analysis, opportunities, challenges, and unmet needs.
  • Pipeline assessment: emerging novel trends under development, and analysis of the most promising late-stage NTM pipeline drugs in clinical development.
  • Analysis of the key dynamics of the nontuberculous mycobacteria drugs market.